The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of early tumor shrinkage and depth of response in patients with advanced biliary tract cancer treated with gemcitabine plus cisplatin or gemcitabine plus S-1: An exploratory analysis of JCOG1113.
 
Naohiro Okano
Honoraria - Bayer Yakuhin; Chugai Pharma; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Chigusa Morizane
Honoraria - Eisai; Merck Sharp & Dohme; Novartis; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Abbvie; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Eisai (Inst); J-Pharma (Inst); Merck (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Takuji Okusaka
Honoraria - AstraZeneca; Bayer; Chugai Pharma; Eisai; Lilly; Meiji Seika Kaisha; MSD; Mundipharma; Nippon Shinyaku; Novartis; Ono Pharmaceutical; Pfizer; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Baxter (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Takara Bio
 
Ryo Sadachi
No Relationships to Disclose
 
Tomoko Kataoka
No Relationships to Disclose
 
Makoto Ueno
Honoraria - AstraZeneca; Daiichi Sankyo; Merck Serono; MSD; Nipro Corporation; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Research Funding - ASLAN Pharmaceuticals (Inst); Astellas Pharma; AstraZeneca (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Masafumi Ikeda
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Gilead Sciences; Kaken Pharmaceutical; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Micron; Novartis; Ono Pharmaceutical; SERVIER; Shire; Takeda; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Masato Ozaka
Honoraria - Bayer; EA Pharma; Eisai; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Kazuya Sugimori
No Relationships to Disclose
 
Akiko Todaka
No Relationships to Disclose
 
Satoshi Shimizu
Research Funding - AstraZeneca (Inst); Baxalta (Inst); Eisai (Inst); IQvia (Inst); Sumitomo Group (Inst); Sumitomo Group (Inst); Yakult Pharmaceutical (Inst)
 
Nobumasa Mizuno
Honoraria - MSD; Yakult Honsha
Consulting or Advisory Role - AstraZeneca
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
Travel, Accommodations, Expenses - Novartis
 
Tomohisa Yamamoto
No Relationships to Disclose
 
Keiji Sano
No Relationships to Disclose
 
Kazutoshi Tobimatsu
No Relationships to Disclose
 
Akio Katanuma
No Relationships to Disclose
 
Atsushi Miyamoto
No Relationships to Disclose
 
Hironori Yamaguchi
Honoraria - Chugai Pharma; Lilly Japan; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Lilly Japan; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Nippon Kayaku; Taiho Pharmaceutical
 
Hiroshi Ishii
Honoraria - Eisai; Taiho Pharmaceutical; Teijin Pharma; TOWA; Yakult Honsha
Consulting or Advisory Role - Ono Pharmaceutical
 
Junji Furuse
Honoraria - Abbvie; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; Kyowa Hakko Kirin; Lilly Japan; Merck; Mochida Pharmaceutical Co. Ltd.; MSD; Mylan; Nihon Servier; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Shionogi; Shire; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Lilly Japan; Merck; MSD; Mundipharma; Novartis; OncoTherapy Science; Ono Pharmaceutical; Otsuka; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Takara Bio; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)